Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Journal of the Neurological Sciences

Volumn 158, Issue 2, 1998, Pages 134-140

  Shoji, Mikio ^a   Matsubara, Etsuro ^a   Kanai, Mitsuyasu ^a   Watanabe, Mitsunori ^a   Nakamura, Tamiko ^a   Tomidokoro, Yasushi ^a   Shizuka, Masami ^a   Wakabayashi, Katsumi ^a   Igeta, Yukifusa ^a   Ikeda, Yoshio ^a   Mizushima, Kazuyuki ^b   Amari, Masakuni ^b   Ishiguro, Koji ^a   Kawarabayashi, Takeshi ^a   Harigaya, Yasuo ^a   Okamoto, Koich ^a   Hirai, Shunsaku ^c  

^a GUNMA UNIVERSITY   (Japan)

^b Geriatrics Research Institute   (Japan)

^c TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

Author keywords

A 1 40; A 1 42; Alzheimer's disease; CSF; Tau

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PEPTIDE FRAGMENTS; REFERENCE VALUES; TAU PROTEINS;

EID: 0032581113     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00122-1     Document Type: Article

References (21)

1. Arai H., Terajima M., Miura M.et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol. 38:1995;649-652.
2. Folstein M.F., Folstein S.E., McHugh P.R. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
3. Ghersi-Egea J.F., Gorevic P.D., Frangione B.et al. Fate of cerebrospinal fluid-bone amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67:1996;880-883.
4. Gravina S.A., Ho L., Eckman C.B.et al. Amyloid β protein (Aβ) in Alzheimer's disease brain: Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). J. Biol. Chem. 270:1995;7013-7016.
5. Harigaya Y., Shoji M., Kawarabayashi T.et al. Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem. Biophys. Res. Commun. 211:1995;1015-1022.
6. Harigaya Y., Shoji M., Nakamura T.et al. Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Intern. Med. 34:1995;481-484.
7. Iizuka T., Shoji M., Harigaya Y.et al. Amyloid β-protein ending at Thr 43 is a minor component of diffuse plaques in the Alzheimer's disease brain. Brain Res. 702:1995;275-278.
8. Iizuka T., Shoji M., Kawarabayashi T.et al. Intracellular generation of amyloid β-protein from amyloid β-protein precursor fragment by direct cleavage with β- and γ-secretase. Biochem. Biophys. Res. Commun. 218:1996;238-242.
9. Kawarabayashi T., Shoji M., Sato M.et al. Accumulation of β-amyloid fibrils in pancreas of transgenic mice. Neurobiol. Aging. 17:1996;215-222.
10. Matsubara E., Hirai S., Amari T.et al. α1-antichymotrypsin as a possible biological marker for Alzheimer-type dementia. Ann. Neurol. 28:1990;561-567.
11. Matsubara E., Frangione B., Ghiso J. Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J. Biol. Chem. 270:1995;7563-7567.
12. McKhann G., Drachman D., Folstein M.et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
13. Mirra SS, Heyman A, McKeel D et al., participating CERAD neuropathologists. The consortium to establish a registry for Alzheimer's disease (CERAD), Part B. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486.
14. Mori H., Hosoda K., Matsubara E.et al. Tau in the cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 186:1995;181-183.
15. Motter R., Vigo-Pelfrey C., Kholodenko D.et al. Reduced of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
16. Nakamura T., Shoji M., Harigaya Y.et al. Amyloid β-protein level in cerebrospinal fluid are elevated in early onset Alzheimer's disease. Ann. Neurol. 36:1994;903-911.
17. Reisberg B., Ferris S.H., Anand R.et al. Functional staging of dementia of the Alzheimer type. Ann. New York Acad. Sci. 435:1984;481-483.
18. Scheuner D., Eckman C., Jensen M.et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2:1996;864-870.
19. Shoji M., Golde T.E., Ghiso J.et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science. 258:1992;126-129.
20. Suzuki N., Cheung T.T., Cai X.D.et al. An increased percentage of long amyloid β-protein precursor (βAPP717) mutants. Science. 264:1994;1336-1340.
21. Vandermeeren M., Mercken M., Vanmechelen E.et al. Detection of τ proteins in normal and Alzheimer's disease cerebral fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61:1993;1828-1834.